Abstract:Objective There is a need for a robust tool to stratify the patient's risk with COVID-19. We assessed the prognostic values of cardiac biomarkers for COVID-19 patients. Methods This is a single-centre retrospective cohort study. Consecutive laboratory-confirmed COVID-19 patients admitted to the Kobe City Medical Center General Hospital from July 2020 to September 2021 were included. We obtained cardiac biomarker values from electronic health records and institutional blood banks. We stratified patients with cardiac biomarkers as high-sensitive troponin I (hsTnI), N-terminal pro-B-type natriuretic peptide (NT-proBNP), creatine kinase (CK) and CK myocardial band (CK-MB), using the clinically relevant thresholds. Prespecified primary outcome measure was all-cause death. Results A total of 917 patients were included. hsTnI, NT-proBNP, CK and CK-MB were associated with the significantly higher cumulative 30-day incidence of all-cause death (hsTnI: <5.0 ng/L group; 4.3%, 5.0 ng/L–99%ile upper reference limit (URL) group; 8.8% and ≥99% ile URL group; 25.2%, p<0.001. NT-proBNP: <125 pg/mL group; 5.3%, 125–900 pg/mL group; 10.5% and ≥900 pg/mL group; 31.9%, p<0.001. CK: <upper (unl)="" 10.6%,="" 16.4%="" 20.4%="" 23.5%,="" 3="" 38.9%,="" 7.8%,="" <unl="" adjusted="" all-cause="" and="" biomarkers.<="" cardiac="" ck-mb:="" death="" each="" for="" group;="" limit="" normal="" of="" p="" p<0.001).="" p Conclusions Elevation of cardiac biomarkers was associated with poor prognosis of COVID-19 patients.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate the prognostic value of cardiac biomarkers in COVID - 19 patients, especially in terms of risk stratification. Specifically, the researchers hope to predict the mortality rate of COVID - 19 patients and the risk of other clinical adverse events by analyzing cardiac biomarkers such as high - sensitivity troponin I (hsTnI), N - terminal pro - B - type natriuretic peptide (NT - proBNP), creatine kinase (CK) and creatine kinase - MB (CK - MB). The main purpose of the study is to determine whether these cardiac biomarkers can be used as effective tools for early risk stratification of COVID - 19 patients, thereby guiding more rational medical management and resource allocation. The research methods include a retrospective cohort study, which included COVID - 19 patients hospitalized in Kobe City Medical Center General Hospital from July 2020 to September 2021. The values of cardiac biomarkers were obtained through electronic health records and institutional blood banks, and patients were stratified according to clinically relevant thresholds. The primary outcome measure was all - cause mortality, and the occurrence of other cardiovascular complications, such as myocardial infarction, heart failure, Takotsubo syndrome, acute pericarditis, stroke and venous thromboembolism, was also evaluated. The research results show that the increase in cardiac biomarker levels is significantly associated with the poor prognosis of COVID - 19 patients, especially the increase in all - cause mortality within 30 days. In addition, these biomarkers can also effectively predict patients who need advanced respiratory support. Although the incidence of cardiovascular complications observed in the study is relatively low, the increase in cardiac biomarkers is still an important indicator of poor prognosis in patients. This suggests that in the management of COVID - 19 patients, monitoring cardiac biomarkers may help to identify high - risk patients at an early stage, so as to take more aggressive treatment measures.

Risk stratification and prognosis prediction using cardiac biomarkers in COVID-19: a single-centre retrospective cohort study